Sign In
Buy NVUS
$3.52
+0 (+0%)
At Close: Aug 17, 2022
Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook
08:00am, Monday, 04'th Jan 2021
Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021
Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript
10:04pm, Monday, 16'th Nov 2020
Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript
Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16
05:04pm, Tuesday, 10'th Nov 2020
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients
Analysts Expect OP Bancorp (NASDAQ:OPBK) Will Post Earnings of $0.19 Per Share
03:30am, Thursday, 22'nd Oct 2020
Brokerages forecast that OP Bancorp (NASDAQ:OPBK) will report earnings of $0.19 per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for OP Bancorp’s earni
OP Bancorp Declares Quarterly Cash Dividend of $0.07 per Share
12:00am, Thursday, 22'nd Oct 2020
OP Bancorp Declares Quarterly Cash Dividend of $0.07 per Share
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
04:31pm, Monday, 14'th Sep 2020
IRVINE, Calif. & BOSTON--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a priv
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
12:00am, Sunday, 07'th Jun 2020
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Negative clinical readouts led to some strong selling in...
Novus Therapeutics stock loses nearly half its value after disappointing drug trial results
01:50pm, Monday, 01'st Jun 2020
Shares of Novus Therapeutics Inc. undefined lost nearly half their value in active trading Monday, after the specialty drug maker announced disappointing...
Novus Therapeutics stock loses nearly half its value after disappointing drug trial results
01:50pm, Monday, 01'st Jun 2020
Shares of Novus Therapeutics Inc. lost nearly half their value in active trading Monday, after the specialty drug maker announced disappointing trial results of its ear infection treatment. Trading v
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
12:30pm, Monday, 01'st Jun 2020
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
12:00am, Monday, 01'st Jun 2020
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Hedge Funds Watching Novus Therapeutics, Inc. (NVUS) From Afar
10:39pm, Saturday, 30'th May 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Novus Therapeutics Reports First Quarter 2020 Financial Results
10:30am, Friday, 15'th May 2020
Novus Therapeutics Reports First Quarter 2020 Financial Results
3 Biotech Stocks Under $3 With 200%-Plus Upside Potential
02:38pm, Tuesday, 12'th May 2020
The healthcare sector took its place among the winners this year, rising 11%, compared to the S&P; 500’s 9% drop. The bottom-line for investors? Wall Street’s focus is on the healthcare space, loc
Phillips Edison & Company, Inc. (“PECO” or the “Company”), an internally-managed real estate investment trust (“REIT”) and one of the nation’s lar
